Author: Okeke, Malachy I.; Okoli, Arinze S.; Diaz, Diana; Offor, Collins; Oludotun, Taiwo G.; Tryland, Morten; Bøhn, Thomas; Moens, Ugo
Title: Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? Document date: 2017_10_29
ID: 175igdfk_9
Snippet: Hazard characterization (ERA step 2) of MVA and MVA-vectored vaccines would require knowledge of: (i) nature and distribution of naturally circulating OPVs that may rescue the MVA during co-infection and superinfection; (ii) recombination between MVA-vectored vaccines and naturally occurring OPVs during co-infection/superinfection of cell cultures, immune-competent and immune-compromised animals; (iii) MVA host restriction in human cells and the .....
Document: Hazard characterization (ERA step 2) of MVA and MVA-vectored vaccines would require knowledge of: (i) nature and distribution of naturally circulating OPVs that may rescue the MVA during co-infection and superinfection; (ii) recombination between MVA-vectored vaccines and naturally occurring OPVs during co-infection/superinfection of cell cultures, immune-competent and immune-compromised animals; (iii) MVA host restriction in human cells and the molecular basis for the restriction; (iv) clonal purity of MVA stocks; (v) genome and transgene stability of MVA and MVA-vectored vaccines following multiple serial passages; (vi) virus and host factors that modulate transgene stability; (vii) effect of the expressed transgene(s) on the virus-host transcriptome, proteome, metabolome and epigenome and (viii) biodistribution and shedding in immune-competent and immune-compromised individuals.
Search related documents:
Co phrase search for related documents- cell culture and host factor: 1, 2, 3, 4, 5, 6, 7, 8
- cell culture and host restriction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cell culture and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77
- cell culture and ii recombination: 1
- cell culture and molecular basis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cell culture and serial passage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cell culture and vi virus: 1
- cell culture and virus host: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clonal purity and Hazard characterization: 1, 2
- clonal purity and MVA stock: 1, 2
- clonal purity and MVA stock clonal purity: 1, 2
- co infection and host factor: 1, 2, 3, 4
- co infection and host restriction: 1, 2
- co infection and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- co infection and ii recombination: 1, 2
- co infection and molecular basis: 1, 2
- co infection and superinfection co infection: 1, 2, 3, 4, 5, 6, 7
- co infection and virus host: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
Co phrase search for related documents, hyperlinks ordered by date